Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Changnian Liu, PhD MD, Bin Liu, MSc, Chunping Xu, PhD, Pan Zhang, Bin Li, Bin Ji, Bin Zhang, Qingjun Liu, PhD, James Zhang, MSc, Chengzhi Yu, PhD

Blood (2019) 134 (Supplement_1): 5141.

https://doi.org/10.1182/blood-2019-123589

Published: 2019

Journal Articles

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies

Bin Li, PhD, Kaili Ren, PhD, Lei Shen, PhD, Peijie Hou, PhD, Zhenqiang Su, PhD, Alessandra Di Bacco, PhD, Jin-Liern Hong, PhD, Aaron Galaznik, PhD, Ajeeta B Dash, PhD, Victoria Crossland, PhD, Paul Dolin, DPhil, Sandor Szalma, PhD

Blood (2018) 132 (Supplement 1): 3298.

https://doi.org/10.1182/blood-2018-99-115017

Published: 2018

Journal Articles

Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study

Ajeeta B Dash, PhD, Jacob Zhang, PhD, Lei Shen, PhD, Bin Li, PhD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Hervé Avet-Loiseau, MDPhD, Nizar Bahlis, MD, Philippe Moreau, Paul Richardson, Alessandra Di Bacco, PhD

Blood (2018) 132 (Supplement 1): 473.

https://doi.org/10.1182/blood-2018-99-114614

Published: 2018

Journal Articles

Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin

Blood (2018) 131 (12): 1325–1336.

https://doi.org/10.1182/blood-2017-07-794875

Published: 2018

Includes: Supplemental data

Journal Articles

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2016) 128 (22): 243.

https://doi.org/10.1182/blood.V128.22.243.243

Published: 2016

Journal Articles

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Blood (2014) 124 (21): 3414.

https://doi.org/10.1182/blood.V124.21.3414.3414

Published: 2014

Journal Articles

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Blood (2014) 123 (5): 632–639.

https://doi.org/10.1182/blood-2013-05-504340

Published: 2014

Includes: Supplemental data

Journal Articles

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

George Mulligan, PhD, David I Lichter, MS, Alessandra Di Bacco, PhD, Stephen J Blakemore, PhD, Allison Berger, PhD, Erik Koenig, Hugues Bernard, William L. Trepicchio, PhD, Bin Li, PhD, Sagar Lonial, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Pieter Sonneveld, MD, PhD, Jesús F San Miguel, MD PhD, Dixie-Lee Esseltine, MD, FRCPC, Matthew Schu, MS

Blood (2011) 118 (21): 1377.

https://doi.org/10.1182/blood.V118.21.1377.1377

Published: 2011

Journal Articles

TNF-α-Mediated Tumor Promotion Is Characterized by Enhanced Vasculogenesis and Generation of Myeloid/Endothelial Vascular Leukoctyes.

Bin Li, PhD, Matthew Pagni, BA, Justin Cates, PhD, D. Brent Polk, MD, Pampee P. Young, MD, PhD

Blood (2007) 110 (11): 3905.

https://doi.org/10.1182/blood.V110.11.3905.3905

Published: 2007

Journal Articles

EPCs Derived from Ex Vivo Expansion of Unmobilized Human Peripheral Blood Co-Express Hematopoietic and Endothelial-Specific Markers and Can Be Derived from Culture of Highly Purified Populations of CD14-Positive Monocytes.

Emerson E. Sharpe, B.S., Amylynn A. Teleron, B.S., Bin Li, Ph.D, Pampee P. Young, M.D./Ph.D

Blood (2004) 104 (11): 2682.

https://doi.org/10.1182/blood.V104.11.2682.2682

Published: 2004

Journal Articles

Enhanced Growth Suppression of Philadephia 1 Leukemia Cells in Mice by Targeting Both BCR-ABL and VEGF through the Antisense Strategy.

Zhong Chao Han, MD, Xiu Li Cong, Bin Li, Ren Chi Yang

Blood (2004) 104 (11): 5257.

https://doi.org/10.1182/blood.V104.11.5257.5257

Published: 2004

Journal Articles

VEGF-VEGF Receptor 1 (Flt-1) Interactions Significantly Modulate Endothelial Progenitor Cell (EPC) Migration but Have Only Minor Effects on the Migration of Differentiated Endothelial Cells.

Bin Li, Ph.D, Amylynn A. Teleron, Charles Lin, Ph.D, Pampee P. Young, M.D Ph.D

Blood (2004) 104 (11): 3229.

https://doi.org/10.1182/blood.V104.11.3229.3229

Published: 2004

Journal Articles

Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages

Yong Jun Liu, Shi Hong Lu, Bin Xu, Ren Chi Yang, Qian Ren, Bin Liu, Bin Li, Min Lu, Feng Ying Yan, Zhi Bo Han, Zhong Chao Han

Blood (2004) 103 (12): 4449–4456.

https://doi.org/10.1182/blood-2003-06-1825

Published: 2004

Journal Articles

Defects in Yolk Sac Hematopoiesis in Mll -Null Embryos

Jay L. Hess, Benjamin D. Yu, Bin Li, Rob Hanson, Stanley J. Korsmeyer

Blood (1997) 90 (5): 1799–1806.

https://doi.org/10.1182/blood.V90.5.1799

Published: 1997

NARROW

ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies

Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study

Prolyl 4-hydroxylase 2 promotes B-cell lymphoma progression via hydroxylation of Carabin

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

Mutational Analysis of Tumor Samples From Patients with Relapsed or Refractory Multiple Myeloma (MM) Highlights the Prevalence of RAS/RAF Pathway Activation and Demonstrates Previously Unreported Mutations in Known Cancer Genes

TNF-α-Mediated Tumor Promotion Is Characterized by Enhanced Vasculogenesis and Generation of Myeloid/Endothelial Vascular Leukoctyes.

EPCs Derived from Ex Vivo Expansion of Unmobilized Human Peripheral Blood Co-Express Hematopoietic and Endothelial-Specific Markers and Can Be Derived from Culture of Highly Purified Populations of CD14-Positive Monocytes.

Enhanced Growth Suppression of Philadephia 1 Leukemia Cells in Mice by Targeting Both BCR-ABL and VEGF through the Antisense Strategy.

VEGF-VEGF Receptor 1 (Flt-1) Interactions Significantly Modulate Endothelial Progenitor Cell (EPC) Migration but Have Only Minor Effects on the Migration of Differentiated Endothelial Cells.

Hemangiopoietin, a novel human growth factor for the primitive cells of both hematopoietic and endothelial cell lineages

Defects in Yolk Sac Hematopoiesis in Mll -Null Embryos

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only